While the restricted CD19 and CD20 expression profile of ALL patients facilitates successful targeting of these B cell-associated antigens, the heterogeneous tumor antigen expression in a wide array of AML makes it more difficult to select an suitable target antigen (Taussig et al., 2005; Levine et al., 2015). This evidence concerns the gene CD19 and acute myeloid leukemia.